Notably, mutations in genes such as FLT3-ITD, ASXL1, TP53, NPM1, CEBPA, and TET2 carry prognostic implications, albeit with varying effects in elderly AML patients compared to adult populations. This evidence concerns the gene TP53 and acute myeloid leukemia.